The Central Laboratory (CL) of the HIV Vaccine Trials Network (HVTN) is constituted by 3 highly experienced Core Laboratories (CoL) that perform state of the art virological and immunological assays that support Phase I/II clinical trials in the U.S. and at several international sites. Complementing the Core studies is a network of 12 collaborating laboratories designated Scientific Emphasis Groups (SEG) that conduct cutting edge developmental research on various topics that are pertinent to the vaccine trials. These include broad areas such as pathogenesis, viral variation host variation, humoral, cellular and mucosal responses to vaccines and viral suppression. An additional SEG will serve to provide a strong linkage between vaccine trials in humans and cognate studies in the non-human primate model. In addition the CL and the HVTN have established a process whereby linkages to the broader scientific community can occur through provision of materials and reagents emanating from the vaccine trials as well as funding for meritorious studies. The CL includes administrative, organizational and management structures that ensure effective communication within the laboratory network as well as between the CL and various functional units of the HVTN.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI046725-04
Application #
6632214
Study Section
Special Emphasis Panel (ZAI1-HSD-A (S1))
Program Officer
D'Souza, Patricia D
Project Start
2000-04-01
Project End
2005-03-31
Budget Start
2003-04-01
Budget End
2004-03-31
Support Year
4
Fiscal Year
2003
Total Cost
$8,314,361
Indirect Cost
Name
Duke University
Department
Surgery
Type
Schools of Medicine
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
McGuire, Erin P; Fong, Youyi; Toote, Christopher et al. (2018) HIV-Exposed Infants Vaccinated with an MF59/Recombinant gp120 Vaccine Have Higher-Magnitude Anti-V1V2 IgG Responses than Adults Immunized with the Same Vaccine. J Virol 92:
Fouda, Genevieve G; Cunningham, Coleen K; McFarland, Elizabeth J et al. (2015) Infant HIV type 1 gp120 vaccination elicits robust and durable anti-V1V2 immunoglobulin G responses and only rare envelope-specific immunoglobulin A responses. J Infect Dis 211:508-17
Yates, Nicole L; Liao, Hua-Xin; Fong, Youyi et al. (2014) Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med 6:228ra39
Tomaras, Georgia D; Haynes, Barton F (2014) Advancing Toward HIV-1 Vaccine Efficacy through the Intersections of Immune Correlates. Vaccines (Basel) 2:15-35
Frey, Sharon E; Peiperl, Laurence; McElrath, M Juliana et al. (2014) Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants. Clin Vaccine Immunol 21:1589-99
Liu, Pinghuang; Williams, Latonya D; Shen, Xiaoying et al. (2014) Capacity for infectious HIV-1 virion capture differs by envelope antibody specificity. J Virol 88:5165-70
Yates, N L; Stacey, A R; Nolen, T L et al. (2013) HIV-1 gp41 envelope IgA is frequently elicited after transmission but has an initial short response half-life. Mucosal Immunol 6:692-703
Eckels, Josh; Nathe, Cory; Nelson, Elizabeth K et al. (2013) Quality control, analysis and secure sharing of Luminex® immunoassay data using the open source LabKey Server platform. BMC Bioinformatics 14:145
Liu, Pinghuang; Yates, Nicole L; Shen, Xiaoying et al. (2013) Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees. J Virol 87:7828-36
Churchyard, Gavin J; Morgan, Cecilia; Adams, Elizabeth et al. (2011) A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). PLoS One 6:e21225

Showing the most recent 10 out of 45 publications